Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. A Randomized Clinical Trial Alan K. Davis, PhD; Frederick S. Barrett, PhD; Darrick G. May, MD; Mary P. Cosimano, MSW; Nathan D. Sepeda, BS; Matthew W. Johnson, PhD; Patrick H. Finan, PhD; Roland R. Griffiths, PhD JAMA Psychiatry, 2020, E1-E9. doi : 10.1001/jamapsychiatry.2020.3285 IMPORTANCE : Major depressive disorder (MDD) is a substantial public health burden, but current treatments have limited effectiveness and adherence. Recent evidence suggests that 1 or 2 administrations of psilocybin with psychological support produces antidepressant effects in patients with cancer and in those with treatment-resistant depression. OBJECTIVE : To investigate the effect of psilocybin [...]
Lire la suitePsychedelics as a Treatment for Alzheimer’s Disease Dementia Simon Andrew Vann Jones and Allison O’Kelly Cornwall Partnership NHS Foundation Trust, Liskeard, United Kingdom Frontiers in Synaptic Neuroscience, August 2020 | Volume 12 | Article 34 doi : 10.3389/fnsyn.2020.00034 Currently, there are no disease-modifying treatments for Alzheimer’s disease (AD) or any other dementia subtype. The renaissance in psychedelic research in recent years, in particular studies involving psilocybin and lysergic acid diethylamide (LSD), coupled with anecdotal reports of cognitive benefits from micro-dosing, suggests that they may have a therapeutic role in a range of psychiatric and neurological conditions due to their potential to stimulate neurogenesis, provoke neuroplastic [...]
Lire la suiteMinor Cannabinoids of Cannabis sativa L. Fabian Thomas & Oliver Kayser Journal of Medical Science, 2019, 88, (3), 141-149. Doi : 10.20883/jms.367 ABSTRACT Cannabinoids from Cannabis sativa L. play an important role as natural products in clinics. The major cannabinoids compromise tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA) and its decarboxylated analogs. In this review, we focus on often neglected minor cannabinoids and discuss biosynthetic and chemical degradation routes to other neglected cannabinoids in Cannabis sativa starting from THCA, CBDA and cannabichromenic acid (CBCA). Based on the literature, patents and scientific reports, essential routes for the chemical modifi cation of cannabinoids are discussed to explain [...]
Lire la suiteCannabis sativa L. CANNABACEAE Rainer W. Bussmann, Ketevan Batsatsashvili, Zaal Kikvidze, Narel Y. Paniagua-Zambrana, Manana Khutsishvili, Inesa Maisaia, Shalva Sikharulidze, and David Tchelidze © Springer Nature Switzerland AG 2020 in K. Batsatsashvili et al. (eds.), Ethnobotany of the Mountain Regions of Far Eastern Europe, Ethnobotany of Mountain Regions, doi : 10.1007/978-3-030-28940-9_33 Synonyms : Cannabis sativa L., Cannabis chinense Delile, Cannabis indica Lam, Cannabis sativa var. indica (Lam.) E. Small & Cronquist R. Local Names : Georgian : კანაფი (k’anapi); ქან (qan) (Grossheim 1952; Ketskhoveli et al. 1971–2011; Makashvili 1991; Fedorov 1984); English : Cannabis Botany and Ecology Annual; stems 50–150 cm, covered with appressed hairs; leaves long petioled, [...]
Lire la suiteResearch Progress of the Antiviral Bioactivities of Natural Flavonoids Lin Wang · Junke Song · Ailin Liu · Bin Xiao · Sha Li · Zhang Wen · Yang Lu · Guanhua Du Natural Products and Bioprospecting, 2020, 10, 271–283 doi : 10.1007/s13659-020-00257-x Abstract Flavonoids are now considered as an indispensable component in a variety of nutraceutical and pharmaceutical applications. Most recent researches have focused on the health aspects of flavonoids for humans. Especially, different flavonoids have been investigated for their potential antiviral activities, and several natural flavonoids exhibited significant antiviral properties both in vitro and in vivo. This review provides a survey of the literature [...]
Lire la suiteDetermination of cannabinoids in Cannabis sativa L. samples for recreational, medical, and forensic purposes by reversed-phase liquid chromatography-ultraviolet detection Sanja Zivovinovic, Ruth Alder, Martina D. Allenspach and Christian Steuer Journal of Analytical Science and Technology, 2018, 9, 27, 1-10 doi : 10.1186/s40543-018-0159-8 Abstract Background : Currently, an increasing demand of cannabis-derived products for recreational and medical use is observed. Therefore, the reliable and fast quantification of cannabinoids in hemp samples is essential for the control of product from Cannabis sativa, L. strains. In general, gas chromatography (GC) is the method of choice for the quantification of cannabinoids whereas this method is time consuming and the [...]
Lire la suiteΔ 9‑Tetrahydrocannabinol Toxicity and Validation of Cannabidiol on Brain Dopamine Levels : An Assessment on Cannabis Duplicity Swapnali Chetia · Gaurab Borah Natural Products and Bioprospecting, 2020, 10, 285–296 doi : 10.1007/s13659-020-00263-z Abstract Δ9-tetrahydrocannabinol (THC) of cannabis is the main psychoactive component which is a global significant concern to human health. Evaluation on THC reported its drastic effect on the brain dopaminergic (DAergic) system stimulating mesolimbic DA containing neurons thereby increasing the level of striatal DA. Cannabidiol (CBD), with its anxiolytic and anti-psychotic property, is potent to ameliorate the THC-induced DAergic variations. Legal authorization of cannabis use and its analogs in most countries led to [...]
Lire la suiteDans 3 heures, le premier webinaire de la série d'événements gratuits de l'IACM commencera, qui se déroulera jusqu'au 3 décembre 2020. Tous les webinaires peuvent être consultés gratuitement jusqu'au 31 mars 2021. Il n'y a donc aucun problème si vous manquez un rendez-vous. O. k. Vous pouvez copier le Magath ici https://new.cannabis-med.org/e2020 15 octobre 2020, 18 heures (CET) Dr. Roger Pertwee Les utilisations thérapeutiques potentielles de certains cannabinoïdes dérivés du cannabis et synthétiques révélées par leurs propriétés pharmacologiques -- Quels sont les médicaments cannabinoïdes approuvés qui ont déjà été développés ? -- Existe-t-il des cannabinoïdes végétaux (phytocannabinoïdes) ayant des propriétés pharmacologiques, pour lesquels des applications thérapeutiques [...]
Lire la suiteDécret no 2020-1230 du 7 octobre 2020 relatif à l’expérimentation de l’usage médical du cannabis NOR : SSAP2021390D Décrets, arrêtés, circulaires TEXTES GÉNÉRAUX MINISTÈRE DES SOLIDARITÉS ET DE LA SANTÉ JOURNAL OFFICIEL DE LA RÉPUBLIQUE FRANÇAISE, le 9 octobre 2020 Publics concernés: professionnels de santé et patients inclus dans l’expérimentation; entreprises ou organismes exploitant un médicament ou un produit; entreprises pharmaceutiques exerçant une activité de distribution en gros de médicaments; Agence nationale de sécurité du médicament et des produits de santé. Objet: modalités de mise en oeuvre de l’expérimentation relative à l’usage médical du cannabis. Entrée en vigueur: le texte entre en vigueur le lendemain [...]
Lire la suiteThe EU CBD CONSUMER REPORT SERIES : Segmentation & Archetypes Executive Summary, Volume II New Frontier Data 2019-2020, European CBD Survey, 7 pp. As the active ingredient cannabidiol (CBD) from cannabis has undergone an explosive growth in popularity, consumers in the European Union (EU) are increasingly being exposed to information and products—and trying to understand the cannabinoid’s potential and how it might best fit into their lives. As of February 2020, within the EU’s 27 member states, its 445 million citizens find increasing opportunities to participate in the burgeoning CBD market, and brands will play a critical role in defining their experiences. Having already [...]
Lire la suite